MA27674A1 - Derives d'indole tricycliques et leur utilisation dans le cadre du traitement de la maladie d'alzheimer - Google Patents

Derives d'indole tricycliques et leur utilisation dans le cadre du traitement de la maladie d'alzheimer

Info

Publication number
MA27674A1
MA27674A1 MA28563A MA28563A MA27674A1 MA 27674 A1 MA27674 A1 MA 27674A1 MA 28563 A MA28563 A MA 28563A MA 28563 A MA28563 A MA 28563A MA 27674 A1 MA27674 A1 MA 27674A1
Authority
MA
Morocco
Prior art keywords
alzheimer
disease
treatment
indole derivatives
tricyclic indole
Prior art date
Application number
MA28563A
Other languages
English (en)
Inventor
Emmanuel Hubert Demont
Sally Redshaw
Daryl Simon Walter
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA27674A1 publication Critical patent/MA27674A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA28563A 2003-04-23 2005-10-19 Derives d'indole tricycliques et leur utilisation dans le cadre du traitement de la maladie d'alzheimer MA27674A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0309221.0A GB0309221D0 (en) 2003-04-23 2003-04-23 Novel compounds

Publications (1)

Publication Number Publication Date
MA27674A1 true MA27674A1 (fr) 2005-12-01

Family

ID=9957152

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28563A MA27674A1 (fr) 2003-04-23 2005-10-19 Derives d'indole tricycliques et leur utilisation dans le cadre du traitement de la maladie d'alzheimer

Country Status (16)

Country Link
US (1) US20060229302A1 (fr)
EP (1) EP1620438A1 (fr)
JP (1) JP2006524206A (fr)
KR (1) KR20050111797A (fr)
CN (1) CN1809573A (fr)
BR (1) BRPI0409622A (fr)
CA (1) CA2523291A1 (fr)
CO (1) CO5700829A2 (fr)
GB (1) GB0309221D0 (fr)
IS (1) IS8135A (fr)
MA (1) MA27674A1 (fr)
MX (1) MXPA05011365A (fr)
NO (1) NO20055442L (fr)
RU (1) RU2005136370A (fr)
WO (1) WO2004094430A1 (fr)
ZA (1) ZA200508041B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20040762A1 (es) * 2002-11-27 2004-11-06 Elan Pharm Inc Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer
GB0328900D0 (en) * 2003-12-12 2004-01-14 Glaxo Group Ltd Novel compounds
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
GB0411404D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
BRPI0515383A (pt) * 2004-09-21 2008-07-22 Pfizer Prod Inc n-etil hidroxietilamina útil no tratamento de condições do snc
GB0422765D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
GB0422755D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
GB0422766D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
WO2006088705A1 (fr) * 2005-02-14 2006-08-24 Wyeth Guanidine de terphenyle en tant qu'inhibiteurs de la $g(b)-secretase
GB0506562D0 (en) * 2005-03-31 2005-05-04 Glaxo Group Ltd Novel compounds
MX2007012341A (es) 2005-04-08 2008-02-12 Comentis Inc Compuestos que inhiben actividad beta-secretasa y metodos de uso de los mismos.
WO2007019078A2 (fr) * 2005-08-03 2007-02-15 Merck & Co., Inc. Inhibiteurs de la beta-secretase tricyclique pour traiter la maladie d'alzheimer
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
US7872009B2 (en) * 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
EP1971598A1 (fr) * 2005-11-21 2008-09-24 Amgen Inc. Modulateurs de beta-secretase et procedes d'utilisation associes
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
CA2687608C (fr) 2007-05-25 2013-07-02 Amgen Inc. Composes d'hydroxyethylamine substitues en tant que modulateurs de la beta-secretase et methodes d'utilisation
CL2008001500A1 (es) 2007-05-25 2008-12-26 Amgen Inc Compuestos derivados de hidroxietil amina sustituidas, moduladores de betasecretasa; proceso de preparacion de dichos c ompuestos; composicion farmaceutica que los comprende; y su uso para tratar un trastorno neurologico, tal como alzheimer, sindrome de down, demencia degenerativa, entre otros.
FR2919288B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6- carboxamides, leur preparation et leur application en therapeutique.
FR2919285B1 (fr) 2007-07-27 2012-08-31 Sanofi Aventis Derives de 1-oxo-isoindoline-4-carboxamides et de 1-oxo- 1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur preparation et leur application en therapeutique.
KR20100050485A (ko) * 2007-07-27 2010-05-13 사노피-아벤티스 1,2,3,4-테트라히드로피롤로[1,2-ａ]피라진-6-카르복스아미드 및 2,3,4,5-테트라히드로피롤로[1,2-ａ][1,4]-디아제핀-7-카르복스아미드 유도체, 그의 제조 및 치료적 용도
FR2919286A1 (fr) 2007-07-27 2009-01-30 Sanofi Aventis Sa Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique.
FR2919289B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]- diazepine-7-carboxamides, leur preparation et leur application en therapeutique.
WO2013148130A1 (fr) * 2012-03-29 2013-10-03 Oklahoma Medical Research Foundation Inhibition du clivage de la mémapsine 1 dans le traitement du diabète
RU2764243C2 (ru) * 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
WO2019075358A1 (fr) * 2017-10-13 2019-04-18 Ghosh Arun K Inhibiteurs de bace1 pour le traitement de la maladie d'alzheimer
US12043631B2 (en) 2017-10-13 2024-07-23 Purdue Research Foundation BACE1 inhibitors for the treatment of Alzheimer's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033795A1 (fr) * 1997-02-04 1998-08-06 The Regents Of The University Of California Inhibiteurs de cathepsine d nanomolaires et non peptidiques
US6207664B1 (en) * 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
CA2410680A1 (fr) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Composes pour le traitement de la maladie d'alzheimer

Also Published As

Publication number Publication date
EP1620438A1 (fr) 2006-02-01
KR20050111797A (ko) 2005-11-28
AU2004232475A1 (en) 2004-11-04
RU2005136370A (ru) 2006-05-27
CA2523291A1 (fr) 2004-11-04
CO5700829A2 (es) 2006-11-30
ZA200508041B (en) 2007-02-28
US20060229302A1 (en) 2006-10-12
MXPA05011365A (es) 2005-11-28
GB0309221D0 (en) 2003-06-04
BRPI0409622A (pt) 2006-04-18
WO2004094430A1 (fr) 2004-11-04
JP2006524206A (ja) 2006-10-26
IS8135A (is) 2005-11-21
NO20055442L (no) 2005-11-17
CN1809573A (zh) 2006-07-26

Similar Documents

Publication Publication Date Title
IS8135A (is) Þríhringtengdar indólafleiður og notkun þeirra til að meðhöndla Alzheimers-sjúkdóm
EP2011513A4 (fr) Agents thérapeutiques employés dans le cadre de la maladie d'alzheimer et du cancer
EP1689348A4 (fr) Composition d'oligosaccharides et leur utilisation dans le traitement d'infection
EP1465854A4 (fr) Derives de chalcone et leur utilisation dans le traitement de maladies
MA29084B1 (fr) Derives d'indenyle et leur utilisation dans le traitement de troubles neurologiques
EP1651195A4 (fr) Procedes pharmaceutiques, posologies et formes posologiques pour le traitement de la maladie d'alzheimer
EP1578253A4 (fr) Prevention et traitement d'une maladie synucleopathique
EP1490050A4 (fr) Methodes de traitement de la maladie d'alzheimer et amelioration neuro-cognitive
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
ATE374204T1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
HUP1500560A2 (en) Thioflavin derivatives and their use in diagnosis and treatment of alzheimer's disease
NO20022680L (no) Farmasoytiske kombinasjoner og deres anvendelse ved behandling av gastrointestinale forstyrrelser
DK1392287T3 (da) Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom
EP1994152A4 (fr) Peptides efficaces dans le cadre du traitement de tumeurs et d'autres affections nécessitant l'élimination ou la destruction de cellules
EP1644479A4 (fr) Macromolecules et molecules synthetiques fonctionnelles pour l'administration de genes
EP1007048A4 (fr) Identification d'agents utiles dans le traitement de la maladie d'alzheimer
EP1656359A4 (fr) Inhibiteurs macrocycliques de la beta-secretase destines au traitement de la maladie d'alzheimer
MA28806B1 (fr) Derives d'arylsulfonylstilbene destines au traitement de l'insomnie et de conditions apparentees
NO20006113L (no) Anvendelse av cyklosporiner i behandlingen av inflammatoriske autoimmune sykdommer
NO20024924D0 (no) Anvendelse av bradykardiale substanser ved behandling av myokardiale sykdommer i forbindelse med hypertrofi og nyemedikamentkombinasjoner
EP1474126A4 (fr) Traitements de la neurotoxicite dans la maladie d'alzheimer
FR2835255B1 (fr) Test pour identifier des inhibiteurs de beta-secretases, procede de criblage de ces inhibiteurs, et nouveaux inhibiteurs de beta-secretases pour leur utilisation dans le traitement de la maladie d'alzheimer
EP1855679A4 (fr) Inhibiteurs de la beta-secretase d'aminomethyle dans le traitement de la maladie d'alzheimer
EP1567556A4 (fr) Immunotoxine recombinante et son utilisation dans le traitement de tumeurs
EP1532258A4 (fr) Traitement du dysfonctionnement vasculaire et maladie d'alzheimer